September 26, 2024

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category
Go back

We are pleased to announce significant news: the first sustainable and biodegradable pregnancy test in Europe developed by Zamann Pharma Support, under the Terra Trust house brand, has been nominated for the prestigious DQS Sustainability Award 2024 in the “Sustainable Innovation” category. This nomination is a confirmation of their tireless commitment to environmental protection and sustainable innovation.

Every year, the DQS Sustainability Awards recognize companies that are pioneers in sustainability. It is one of the most important awards in the field of sustainability, recognizing companies, regardless of their size, for their innovative approaches to promoting environmental protection and social responsibility. This nomination is not only a recognition for Terra Trust, but underscores how necessary sustainable solutions have become in all areas of life, including the healthcare industry.

For Terra Trust, this nomination symbolizes much more than just a recognition of their technical innovation. It highlights the growing importance of environmental protection in a sector traditionally characterized by plastic waste and environmentally harmful disposables. Their product represents a new generation of pregnancy tests that protect the environment without compromising on quality or accuracy.

More Information in German / Original News:

Sustainability Award 2024 TerraTrustDownload

Our latest News

discover more
New approach for T-cell immunotherapy against malignant brain tumors

New approach for T-cell immunotherapy against malignant brain tumors

Researchers at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) have developed a promising cellular immunotherapy for the treatment of glioblastomas: They equipped T cells with a receptor that recognizes a protein of the brain tumors that is responsible for the dangerous stem cell properties. The therapeutic T cells directed […]

read more
RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

RNA Origami: Artificial Cytoskeletons to Build Synthetic Cells

Synthetic biologists from Heidelberg University create nanotubes folded from the natural RNA biomolecule With the long-term goal of creating living cells from non-living components, scientists in the field of synthetic biology work with RNA origami. This tool uses the multifunctionality of the natural RNA biomolecule to fold new building blocks, making protein synthesis superfluous. In […]

read more
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression HEIDELBERG, Germany, March 06, 2024 – Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp